FULC (Fulcrum Therapeutics) Cash per Share: $4.18 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FULC Fulcrum Therapeutics Inc FULC
44 GF Score
Price $3.73
GF Value $32.03
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Fulcrum Therapeutics Cash per Share?

Fulcrum Therapeutics FULC +0.95% 44 Cash per Share is $4.18 as of Jun. 2026. GuruFocus rates FULC with a GF Score™ of 44/100 and a GF Value™ of $32.03 (Possible Value Trap). The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Fulcrum Therapeutics's Cash per Share for the quarter that ended in Jun. 2026 was $4.18.

Fulcrum Therapeutics  (NAS:FULC) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Fulcrum Therapeutics Cash per Share Related Terms

Fulcrum Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Fulcrum Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulcrum Therapeutics Cash per Share Chart

Fulcrum Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only 5.37 3.90 3.82 4.47 5.29

Fulcrum Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.96 3.71 5.29 5.00 4.18
FULC
44GF Score
Fulcrum Therapeutics Inc FULC
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulcrum Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Fulcrum Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=352.306/66.58
=5.29

Fulcrum Therapeutics's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=318.84/76.29
=4.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $4.18 mean?
Fulcrum Therapeutics (FULC) has a Cash per Share of $4.18 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Fulcrum Therapeutics and its competitors.
Is Fulcrum Therapeutics' Cash per Share too high?
Fulcrum Therapeutics' current Cash per Share is $4.18. Overall, Fulcrum Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fulcrum Therapeutics' Cash per Share compare to AGEN and IRD?
Fulcrum Therapeutics' Cash per Share of $4.18 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Fulcrum Therapeutics and its competitors. Fulcrum Therapeutics's current Cash per Share is $4.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulcrum Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fulcrum Therapeutics (FULC) is currently considered Possible Value Trap. The stock's GF Value™ is $32.03, compared to a current price of $3.73 — trading 88.4% below its estimated fair value. The current Cash per Share is $4.18. Fulcrum Therapeutics' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Fulcrum Therapeutics (FULC), the current Cash per Share is $4.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulcrum Therapeutics (FULC) Overvalued in 2026?

Based on GuruFocus' analysis, Fulcrum Therapeutics stock appears to be undervalued. The current stock price of $3.73 is trading 88.4% below its estimated GF Value™ of $32.03. GuruFocus considers Fulcrum Therapeutics to be Possible Value Trap.

Key valuation signals for FULC:

  • Cash per Share: $4.18
  • GF Value™: $32.03 vs. price of $3.73 (88.4% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the FULC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fulcrum Therapeutics Business Description

Address 26 Landsdowne Street, Cambridge, MA, USA, 02139
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
44GF Score

Get the complete analysis for FULC

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.73
Price
$32.03
GF Value